Lessons from gefitinib-induced interstitial lung disease: Pharmacovigilance for erlotinib in Japan.

MLA

Nishimura, Tsutomu, et al. “Lessons from Gefitinib-Induced Interstitial Lung Disease: Pharmacovigilance for Erlotinib in Japan.” International Journal of Risk & Safety in Medicine, vol. 21, no. 3, Apr. 2009, pp. 161–67. EBSCOhost, https://doi.org/10.3233/JRS-2009-0475.

APA

Nishimura, T., Tada, H., & Fukushima, M. (2009). Lessons from gefitinib-induced interstitial lung disease: Pharmacovigilance for erlotinib in Japan. International Journal of Risk & Safety in Medicine, 21(3), 161–167. https://doi.org/10.3233/JRS-2009-0475

Chicago

Nishimura, Tsutomu, Harue Tada, and Masanori Fukushima. 2009. “Lessons from Gefitinib-Induced Interstitial Lung Disease: Pharmacovigilance for Erlotinib in Japan.” International Journal of Risk & Safety in Medicine 21 (3): 161–67. doi:10.3233/JRS-2009-0475.